NCT06537908View on ClinicalTrials.gov

Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Anti-PD-1/PD-L1 antibodies

Anti-PD-1/PD-L1 Intravenous injection for at least 6 months

DRUG

Anti-VEGF

Anti-VEGF Intravenous injection for at least 6 months

Trial Locations (1)

Unknown

RECRUITING

Zhongshan Hospital Fudan university, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER